IONIS 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: Ionis reported strong Q2 and first-half 2026 results, with revenue of $268M in Q2 and $514M YTD, up 56% and 69% year over year excluding a prior-year one-time payment. Commercial revenue rose to $119M in Q2 and $226M YTD, driven mainly by DAWNZERA, while TRYNGOLZA contributed $5M in Q2 and $32M YTD, with Q2 sales impacted by an April 1 WAC price reduction. R&D revenue was $149M in Q2 and $288M YTD. The company ended Q2 with $2.1B in cash and reiterated 2026 guidance: revenue of $875M-$900M, TRYNGOLZA sales of $100M-$110M, DAWNZERA sales of $110M-$120M, non-GAAP operating loss of $425M-$475M, and year-end cash above $1.6B.

Company Outlook & Strategy: Management expressed confidence in achieving 2026 guidance and reaching cash flow breakeven by 2028. The company is focused on scaling two independent launches, TRYNGOLZA and DAWNZERA, while preparing for Zilganersen’s expected launch later in 2026. Ionis also highlighted a broad and expanding pipeline, with near- and midterm catalysts expected to support long-term value creation. Leadership emphasized commercial execution, operating discipline, and continued investment in wholly owned and partnered programs.

Key Industry Trends: The call underscored growing recognition of severe hypertriglyceridemia as a major underserved market, with TRYNGOLZA positioned as the first therapy to reduce triglycerides and acute pancreatitis risk in this population. In hereditary angioedema, DAWNZERA is benefiting from a largely switch-driven market. Broader RNA-based therapeutic innovation remained a theme, with continued interest in neurology, cardiovascular disease, hepatitis B, and rare diseases across Ionis’ partnered pipeline. External catalysts include upcoming data/readouts at ESC and regulatory decisions across multiple geographies.

Operational Highlights: TRYNGOLZA’s launch began strongly, with prescriptions received on day 1 and both doses available in the channel within about a week; access and coverage are expanding across commercial and government payers. DAWNZERA continued to gain share in HAE prophylaxis, with growing repeat prescribing and positive physician/patient feedback. Zilganersen launch preparations are advanced, including an expanded access program, customer-facing team buildout, disease awareness efforts, and patient services infrastructure. The company also advanced ION775 into Phase IIb and initiated ION337 in Dravet syndrome.

Challenges & Risks: The key disappointment was Eplontersen in CARDIO-TTRansform, which failed to meet its primary endpoint in ATTR cardiomyopathy despite favorable biomarker and safety outcomes; further analysis and ESC presentation are planned. Commercially, TRYNGOLZA’s second-quarter sales were temporarily reduced by the WAC cut ahead of broader launch. Management also noted that DAWNZERA penetration will take time because HAE prophylaxis is a switch market. As usual, regulatory and development risks remain across the pipeline and outside the U.S.

Key Analyst Questions & Responses: No analyst Q&A was included in the provided transcript excerpt, so there were no specific analyst questions or management responses to summarize.